Media coverage about Icon (NASDAQ:ICLR) has been trending somewhat positive recently, according to Accern. The research group identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Icon earned a news sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the medical research company an impact score of 47.4804947079308 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have effected Accern’s analysis:
Shares of ICLR stock traded up $0.72 during trading on Friday, reaching $122.21. 214,049 shares of the company’s stock were exchanged, compared to its average volume of 281,404. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.95 and a quick ratio of 1.95. Icon has a twelve month low of $76.46 and a twelve month high of $124.65. The firm has a market cap of $6,609.24, a price-to-earnings ratio of 23.82, a price-to-earnings-growth ratio of 1.73 and a beta of 0.45.
Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, February 15th. The medical research company reported $1.43 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.02. Icon had a net margin of 16.01% and a return on equity of 27.55%. The business had revenue of $455.10 million for the quarter, compared to analyst estimates of $455.66 million. During the same quarter in the prior year, the business posted $1.33 EPS. Icon’s revenue for the quarter was up 4.6% compared to the same quarter last year. equities research analysts anticipate that Icon will post 6.02 EPS for the current fiscal year.
A number of research firms recently commented on ICLR. BidaskClub raised shares of Icon from a “sell” rating to a “hold” rating in a research report on Friday, March 9th. KeyCorp reissued a “buy” rating and set a $130.00 target price on shares of Icon in a research report on Thursday, January 11th. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a research report on Wednesday, December 27th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a research report on Sunday, December 31st. Finally, SunTrust Banks reissued a “buy” rating and set a $133.00 target price on shares of Icon in a research report on Monday, January 22nd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $126.00.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Icon (ICLR) Stock Price” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/18/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-icon-iclr-stock-price.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.